To begin with, Sheer said to be honest about the outcome. “Tell the patient ‘Maybe’ and ‘We will try.’ Have a plan A and plan ...

The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is increasing in clinical trials to treat overlapping ...

Researchers say GLP-1 drugs prescribed for weight loss like Ozempic and Mounjaro are more effective at reducing heart health ...

A recent study reveals significant barriers to GLP-1 RA access for diabetes and obesity patients, highlighting racial disparities and high costs. An alarming 40% of orders for glucagon-like peptide-1 ...

Patients with T2D and overweight/obesity starting GLP-1 therapy may experience a small but statistically significant increase ...

Preliminary study shows GLP-1 receptor agonists alter alcohol response, suggesting potential for reducing cravings and ...

Researchers have identified that glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which are widely used to control type ...

The percentage of patients with a GLP-1 RA prescription before metabolic and bariatric surgery increased from 5.6% to 26.9% from 2020 to 2024.

Trump's pledge to slash GLP-1 drug prices sends Novo Nordisk and Eli Lilly shares tumbling, raising questions about the ...

In children and adolescents with type 2 diabetes (T2D) or obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improve glycemic, weight, and cardiometabolic outcomes.

Treatment with GLP-1 RAs was linked to decreased risks for all-cause mortality and MACE in patients with psoriasis when compared with other antidiabetic or obesity drugs.

People with obesity and type 2 diabetes who undergo metabolic surgery live longer and face fewer serious health problems.